Tocilizumab, an immunosuppressive drug blocking IL-6 receptors, has shown a seemingly positive effect in patients with COVID-19 [51,52]; however, because of adverse effects, new candidate molecules that are more effective and/or act on the level of transcription or translation of IL-6 are needed [23]. This evidence concerns the gene IL6 and COVID-19.